The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome

Leukemia

Volumn 15, Issue 11, 2001, Pages 1758-1768

  Miyamoto, N ^a   Sugita, K ^a   Goi, K ^a   Inukai, T ^a   Iijima, K ^a   Tezuka, T ^a   Kojika, S ^a   Nakamura, M ^a   Kagami, K ^a   Nakazawa, S ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

11q23 translocation; AG490; B precursor ALL; JAK2 inhibitor; Philadelphia chromosome

Indexed keywords

5 (2,2 DICYANOVINYL) 2 NITROPHENOL; BCR ABL PROTEIN; BRUTON TYROSINE KINASE; ERBSTATIN; GENISTEIN; JANUS KINASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; THYMIDINE; TRITIUM; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; BIOLOGY; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 11; CLINICAL STUDY; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; LYMPHOID CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; STEM CELL; T LYMPHOCYTE;

EID: 0035157978     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402260     Document Type: Article

References (46)

1. Protein-tyrosine kinase
2. Cytokine receptor signalling
3. Signaling through the hematopoietic cytokine receptors
4. STATs: Signal transducers and activators of transcription
5. Jaks and STATs branch out
6. STATs and gene regulation
7. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction
8. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ signal transduction pathway
9. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
10. Jak2 deficiency defines an essential development checkpoint in definitive hematopoiesis
11. Jak2 is essential for signaling through a variety of cytokine receptors
12. Leukemia and the disruption of normal hematopoiesis
13. Acute lymphoblastic leukemia
14. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotypic leukemic cell line
15. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia
16. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
17. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors
18. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors
19. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases
20. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus Kinase 2 and Shc in human blood platelets
21. Mechanisms of glucocorticoid resistance in human leukemic cells: Implication of abnormal 90 and 70 kDa heat shock proteins
22. Leukemic cell with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF
23. Participation of granulocyte colony-stimulating factor in the growth regulation of leukemia cells from Philadelphia chromosome-positive acute leukemia and blast crisis of chronic myeloid leukemia
24. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome
25. P210 Bcr-Abl interacts with the interleukin 3 receptor βc subunit and constitutively induces its tyrosine phosphorylation
26. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
27. Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK
28. Tyrosine kinase inhibition: An approach to drug development
29. bcr-abl tyrosine kinase activity induces K562 to differentiate
30. bcr-abl autokinase activity in K562 chronic myelogenous leukemia
31. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines
32. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
33. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
34. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis
35. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells
36. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
37. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases
38. Role of btk in B cell development and signaling
39. Jak2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells
40. Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis
41. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
42. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
43. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
44. Clinical efficacy and safty of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
45. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
46. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells